Effect of glucagon-like peptide-1 receptor agonists on renal function: A meta-analysis of randomized controlled trials
A class of injectable medications known as GLP-1 agonists, sold in Canada under the brand names Ozempic and Wegovy, are approved to treat Type 2 diabetes and obesity, respectively
While some peptides currently circulating in the wellness marketplace may eventually become validated therapies through clinical trials such as retatrutide, which is currently in late-stage trials and likely to receive FDA approval others may disappear as scientific scrutiny catches up with the hype
For more details, please visit the [How to Use page]
Theranostics 2018;8:23755
By purchasing this product, the purchaser confirms that it will be used exclusively for lawful research purposes and accepts full responsibility for its possession, handling, and use